Integrated Quantitative Investments LLC Takes Position in CareDx, Inc (NASDAQ:CDNA)

Integrated Quantitative Investments LLC bought a new stake in CareDx, Inc (NASDAQ:CDNA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,162 shares of the company's stock, valued at approximately $325,000.

Several other hedge funds also recently bought and sold shares of the company. Quarry LP acquired a new stake in CareDx in the 3rd quarter worth approximately $27,000. Plato Investment Management Ltd boosted its position in shares of CareDx by 34.1% in the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after acquiring an additional 1,370 shares during the period. Captrust Financial Advisors acquired a new stake in shares of CareDx in the third quarter worth $271,000. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in CareDx by 41.5% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock worth $200,000 after acquiring an additional 2,742 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new position in CareDx during the 4th quarter valued at $208,000.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on CDNA shares. HC Wainwright dropped their price objective on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. StockNews.com upgraded CareDx from a "hold" rating to a "buy" rating in a research note on Wednesday, February 26th. Wells Fargo & Company upgraded CareDx from an "underweight" rating to an "equal weight" rating and reduced their price objective for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, Stephens restated an "overweight" rating and set a $40.00 price objective on shares of CareDx in a research report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $31.83.

Remove Ads

CareDx Price Performance

Shares of NASDAQ:CDNA traded down $0.96 during midday trading on Thursday, reaching $18.09. The company's stock had a trading volume of 253,855 shares, compared to its average volume of 853,803. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84. The business's fifty day simple moving average is $20.41 and its 200-day simple moving average is $22.88. The company has a market capitalization of $1.00 billion, a P/E ratio of -6.65 and a beta of 2.18.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative net margin of 45.90% and a negative return on equity of 53.70%. The firm had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. On average, analysts forecast that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.